-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Measuring harmful huntingtin protein in the brain’s bath water
4 min read
How will we know whether HD-lowering treatments are working? New advancements in the detection of mutant huntingtin.
-
A faulty filter? Blood vessel changes in Huntington's disease
7 min read
New research reveals blood vessel changes that could contribute to problem in HD
-
Lighting the way: A new biomarker for Huntington’s disease
7 min read
A new biomarker reveals brain changes in early Huntington's disease.
-
Novel research technique suggests an antioxidant gene protects vulnerable neurons
8 min read
Researchers use a new technique in an HD mouse to uncover a gene, Gpx6, that is protective to vulnerable neurons.
-
Building a Better Mouse(trap): A New Model of Huntington’s Disease
7 min read
New mouse model gives insights into Huntington's disease
-
Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
6 min read
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-
2015 Huntington's Disease Therapeutics Conference: Day 3
10 min read
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 2
8 min read
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 1
10 min read
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-
Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
4 min read
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
